Amylyx Takes Action to Halt ALS Drug Sales and Streamline Operations

Thursday, 4 April 2024, 16:54

Amylyx has made a strategic decision to withdraw its ALS drug from the market and downsize its workforce by 70%. While new prescriptions are no longer permitted, the company will supply Relyvrio to existing patients at no cost. This move marks a significant shift in Amylyx's business strategy and impacts both the company and ALS patients.

https://store.livarava.com/1d62fa35-f2be-11ee-895e-87cc5c87fb08.jpg — Amylyx Takes Action to Halt ALS Drug Sales and Streamline Operations

Amylyx Halts ALS Drug Sales and Staff Reduction

Following a major decision, Amylyx has chosen to withdraw its ALS drug from the market and slash its workforce by 70%. This move comes with both challenges and opportunities for the company and patients.

Relyvrio Offered at No Charge to Existing Patients

Amylyx will provide Relyvrio free of charge to patients currently using the medication. Despite the halt in new prescriptions, ongoing patients will continue their treatment without financial burden.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.